



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

American Medical Association Accepts Recommendation for CPT Code for Central Arterial Pressure Waveform Analysis

Sydney, Australia: Tuesday, 31st March 2015: Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical technology company and manufacturer of the Uscom BP+, notes that the American Medical Association (**AMA**) has posted its Current Procedural Terminology (**CPT**) Editorial Panel actions from its February 2015 meeting.

Key Points

- AMA accepted recommendation for a new Category I CPT code (9300X1) to cover the “non-invasive calculation and analysis of central arterial pressure waveforms with interpretation and report”
- CPT code is a critical step to gain reimbursement coverage in the United States
- Uscom BP+ noninvasively measures the central arterial pulse pressure waveforms and blood pressures and has US FDA clearance
- AMA does not include proprietary references nor recommend a specific medical device

Uscom notes that the AMA CPT Editorial Panel has recommended accepting the Renal Physicians Association application for addition of a new Category I CPT code (9300X1) for the “non-invasive calculation and analysis of central arterial pressure waveforms with interpretation and report”. This Code is intended to replace the existing temporary Category III CPT code (0311T). Uscom also notes that the exact wording of the Code is yet to be finalized and may change prior to publication.

Uscom CEO Assoc. Prof. Rob Phillips said “*This AMA Editorial Panel decision is an important step in the process of U.S. reimbursement for clinicians measuring and analysing central arterial pressure waveforms, and is highly important for the U.S. adoption of the Uscom BP+. The BP+ is U.S. patent protected with an innovative approach to the measurement of pulse pressure waveforms and central blood pressure, and has been reported as the device with the greatest clinical applicability in this field by researchers from the University of Cambridge, Weill Cornell Medical College, the University of California and the Wales Heart Research Institute.*

While a number of medical devices may potentially offer similar central blood pressure measurements sought to be reimbursed under the preliminary Category 1 CPT code, we believe this AMA Editorial Panel decision is a key step to broader adoption of our technology in the world's largest healthcare market.”

CPT codes are reserved for those procedures that are performed by many physicians and other qualified health care professionals across the United States and have US FDA clearance.

The annual release of the updated CPT codes is timed to coincide with the annual Medicare Physician Fee Schedule (**MPFS**). Following the creation of the new CPT Category I code, the Code is surveyed as part of the AMA/Specialty Society RVS Update Committee's (**RUC**) review. The RUC makes recommendations to the Centers for Medicare and Medicaid Services (**CMS**) on which contribute to the calculation of the Medicare fee for the service, as well as for commercial insurance contracted rates. The new Category I CPT code is set to be released by the AMA Editorial Panel on August 31st 2015, and the final Medicare payment rates will be published by CMS in November 2015. A summary of the panel actions are located on the AMA website at <https://download.ama-assn.org/resources/doc/cpt/x-pub/feb-2015-summary-of-panel-actions.pdf>

Reference: McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014; doi:10.1093/eurheartj/eh565



Uscom Limited

ABN 35 091 028 090

Suite 1, Level 7, 10 Loftus Street

Sydney NSW 2000 Australia

T +612 9247 4144 F +612 9247 8157

www.uscom.com.au

MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technology. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. BP+ uses a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Assoc. Prof. Rob Phillips
Executive Chairman
rob@uscom.com.au

Catherine Officer
Company Secretary
secretary@uscom.com.au